
Half of all trials registered on a US clinical study database are not being published in public journals. This is …

Clinical trial data firm CluePoints has announced three new appointments to its global team. John Colby (pictured) and Elizabeth Polvent join …

Alexion Pharmaceuticals UK has expressed ‘concern’ that NICE has not yet allowed its rare disease treatment Soliris to be formally …
SHL first introduced the Amber™ auto injector utilizing Pushclick™ technology at the PDA (Parental Drug Association) event in Basel, Switzerland …
The UK drugs regulator is proposing new rules that could see pharma update safety information for their medicines online, whilst …

An independent data monitoring committee has told Roche to halt a study of its experimental lung cancer drug MetMab due …

Bayer Group says sales of its blood thinner Xarelto will be higher than it had predicted, with peak annual sales …

The Cello Group has unified all its health-orientated agencies in order to operate under one umbrella brand called Cello Health. …

GlaxoSmithKline is seeking a new licence for its blood disorder drug Promacta in patients with severe aplastic anaemia. Specifically, the …

Neil Flash has joined healthcare agency dna Medical Communications as the managing director for its UK team. Flash joined dna …

It makes sense, doesn’t it? You have a drug that’s effective for a certain disease, but no patients. What do …

The government is to pledge that insurance companies will not be sold patients’ health records via the care.data information sharing …

The government has launched a consultation which aims to establish whether doctors are being held back from using innovative treatments, …

GlaxoSmithKline’s chief executive Sir Andrew Witty received bonuses “lower than they otherwise might have been” last year due to the …

Comms agency Packer Forbes Communications is strengthening its leadership team by appointing Joella Webber as managing director. Webber who was …

Eli Lilly is coming to terms with rejection by NICE after the cost watchdog said it would not recommend Alimta …

Novartis has become the latest pharmaceutical company to allow greater scrutiny of its clinical trial data.

MPs have expressed concerns about security in the delayed NHS care.data programme which will see medical information routinely swapped between …

Novartis has confirmed that it will cease all of its pharmaceutical operations at its Horsham, West Sussex site this year. …

The UK biotechnology industry has ‘missed the boat’ and not fulfilled its potential, according to outgoing UCB chief executive Roch …